Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M. Bolla(Centre Hospitalier Universitaire de Grenoble), M. Piérart(Unknown), J Rafael Pfeffer(Hadassah Academic College), José Lopez Torecilla(Fundación Instituto Valenciano de Oncología), Guy Storme(Mathys (Netherlands)), Abraham Kuten(Rambam Health Care Campus), Carmel Lino Cutajar, J Mattelaer, Alfredo Zurlo(European Organisation for Research and Treatment of Cancer), Laurence Collette(GlaxoSmithKline (Belgium)), L.E.C.M. Blank, Jacques Bernier(Ospedale San Giovanni Bellinzona), René‐Olivier Mirimanoff(University of Lausanne), Padraig Warde(University Health Network), J.B. Dubois(CEA Valduc), Cora N. Sternberg(Cornell University)
Cited by 1,693
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k